Get the Stockscreener App
3.95
1.28%
0.05
After Hours:
3.99
0.04
+1.01%
Orchestra Biomed Holdings Inc stock is traded at $3.95, with a volume of 246.95K.
It is up +1.28% in the last 24 hours and up +45.76% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$3.90
Open:
$3.85
24h Volume:
246.95K
Relative Volume:
0.71
Market Cap:
$213.12M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-2.6333
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
+0.00%
1M Performance:
+45.76%
6M Performance:
+44.16%
1Y Performance:
-25.33%
1-Day Range:
$3.77
$3.99
1-Week Range:
$3.54
$4.01
52-Week Range:
$2.20
$6.50
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
3.95 | 210.42M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Is Orchestra BioMed Holdings Inc. reversing from oversold territoryVolume Spike & AI Driven Stock Reports - newser.com
Can Orchestra BioMed Holdings Inc. stock withstand economic slowdown2025 Market Sentiment & Breakout Confirmation Alerts - newser.com
How sentiment analysis helps forecast Orchestra BioMed Holdings Inc.July 2025 Price Swings & Verified Momentum Stock Watchlist - newser.com
Orchestra BioMed (Nasdaq: OBIO) Nov. 12 call on Medtronic collaboration, pivotal trials - Stock Titan
How to use a screener to detect Orchestra BioMed Holdings Inc. breakouts2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
Is Orchestra BioMed Holdings Inc. stock supported by strong cash flowsPortfolio Update Report & Free Risk Controlled Daily Trade Plans - newser.com
Is this a good reentry point in Orchestra BioMed Holdings Inc.Earnings Risk Report & Advanced Technical Signal Analysis - newser.com
Can Orchestra BioMed Holdings Inc. stock reach $100 price targetWeekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Orchestra BioMed Holdings Inc. stock outperform tech sector in 2025Portfolio Return Report & Fast Gain Swing Trade Alerts - newser.com
Will Orchestra BioMed Holdings Inc. stock recover after recent drop2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - newser.com
What to expect from Orchestra BioMed Holdings Inc. in the next 30 daysInsider Buying & Weekly Market Pulse Alerts - newser.com
The past five years for Orchestra BioMed Holdings (NASDAQ:OBIO) investors has not been profitable - Yahoo Finance
Q3 Earnings Forecast for Orchestra BioMed Issued By B. Riley - MarketBeat
Will Orchestra BioMed Holdings Inc. stock beat EPS estimatesChart Signals & Safe Entry Momentum Tips - newser.com
Exit strategy if you’re trapped in Orchestra BioMed Holdings Inc.Gap Down & Weekly Watchlist for Hot Stocks - newser.com
Custom watchlist performance reports with Orchestra BioMed Holdings Inc.2025 Top Gainers & Stepwise Trade Signal Implementation - newser.com
How currency fluctuations impact Orchestra BioMed Holdings Inc. stock2025 Investor Takeaways & Weekly Top Gainers Alerts - newser.com
Certain Stock Options of Orchestra BioMed Holdings, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2025. - MarketScreener
Certain Pre-Funded Warrants of Orchestra BioMed Holdings, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2025. - MarketScreener
Certain Common Stock of Orchestra BioMed Holdings, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2025. - MarketScreener
Orchestra BioMed Holdings, Inc. Announces Strategic Developments and Financial Milestones - TradingView
What drives Orchestra BioMed Holdings Inc stock priceMarket Depth Overview & Small Capital Portfolio Tips - earlytimes.in
Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial - HMP Global Learning Network
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):